Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Regeneron Pharmaceuticals (REGN) · oqro.io/stocks/REGN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Regeneron Pharmaceuticals insider trading
Have Regeneron Pharmaceuticals insiders bought shares recently?
No open-market purchase by an insider of Regeneron Pharmaceuticals was filed in the last 90 days. The latest on record was on Aug 25, 2017.
How often do Regeneron Pharmaceuticals insiders buy and sell shares?
Since 2006, Regeneron Pharmaceuticals insiders reported 551 open-market purchases and 3,998 sales on Forms 4 and 5, with purchases in 6 different years, most recently 2017.
Who is selling Regeneron Pharmaceuticals stock?
In the last 90 days, 9 insiders of Regeneron Pharmaceuticals (REGN) reported 93 open-market sales worth $59.2M in total on SEC Form 4. The largest seller by value was George L Sing, with $22.3M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade REGN?
Yes. Members of Congress disclosed 4 trades in Regeneron Pharmaceuticals (REGN) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Sen. Alan Armstrong, Rep. Gilbert Ray Cisneros Jr. (CA31), Rep. Julia Letlow (LA05).
When does Regeneron Pharmaceuticals report its next results?
Regeneron Pharmaceuticals's next results are expected on Jan 28, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
REGN price and disclosed activity
+30.4% (+$220.19) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $725.34 on Nov 18, 2025 to $945.53 on Nov 18, 2026 (+30.4%). Disclosed in this range: 31 insider trades, 136 pre-arranged insider sales, 4 Congress trades, and 102 13F position changes for 4 quarters ending in it.
$500$600$700$800$1,000$1,100$945.53
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 171 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biotechnology company based in Tarrytown, New York.
Last 12 months
+30.4%
S&P 500 +10.6% over the same dates
Market value
$97.3B
Close of Nov 18, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 2.22M shares sold short (2.2% of shares outstanding), +3.9% vs the previous count, 2.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
$5.12B
+36.3% vs the same quarter a year earlier
Free cash flow, last 12 months
$3.83B
This quarter $1.48B, a year earlier $1.42B
Net cash
$1.67B
Debt $1.99B, cash $3.66B, at Sep 30, 2026
Net income, last 12 months
$4.82B
Operating profit covers interest 104.2x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 30, 2026.
Since Nov 17, 2025, REGN is up 34.2% and the index fund is up 9.7%: 25 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much REGN moves
A usual day
±1.1%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
4.2%Average distance between the low and the high of a session, over the last 14.
Largest one-day fall
−9.8%May 18, 2026
Largest one-day rise
+13.3%Oct 30, 2026
Deepest fall of the year
−26.1%From the close of Jan 7, 2026 to Jun 1, 2026.
Days of 5% or more
4Out of 252 sessions, in either direction.
Beta 0.4(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2006
Insiders of Regeneron Pharmaceuticals reported 551 open-market purchases and 3,998 sales since 2006; purchases in 6 different years, most recently 2017.
Year
Bought
Sold
2026
—
$64.6M166×166 trades
2025
—
$5.1M8×8 trades
2024
—
$291M366×366 trades
2023
—
$81.6M216×216 trades
2022
—
$159M392×392 trades
2021
—
$364M344×344 trades
2020
—
$12.4B778×778 trades
2019
—
$143M48×48 trades
2018
—
$149M55×55 trades
2017
$212M61×61 trades
$66.8M111×111 trades
2016
$126M42×42 trades
$7.97M13×13 trades
2015
$127M55×55 trades
$228M195×195 trades
2014
$2.02B386×386 trades
$215M167×167 trades
2013
—
$252M202×202 trades
2012
—
$158M208×208 trades
2011
—
$37.9M128×128 trades
2010
$29M4×4 trades
$6.62M38×38 trades
2009
$235K3×3 trades
$2.25M23×23 trades
2008
—
$2.35M102×102 trades
2007
—
$4.21M220×220 trades
2006
—
$8.69M218×218 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last 30 days
Written by software from the filings listed below · Nov 13, 2026
Insiders In the 30 days to Nov 13, 2026, insiders filed 0 open-market purchases and 57 open-market sales (about $49.6M, in 9 filings, by 9 people). Regeneron Pharmaceuticals on OQRO
3 more points, with the facts they come from, are in OQRO Pro.
Latest annual report filed Feb 4, 2026, compared with the one filed Feb 5, 2025. Read the filing
New risk factors in the latest annual report (2 headings)
We face risks associated with tariffs and other trade restrictions, which may have a material adverse impact on our results of operations and financial condition.
There are inherent risks related to our increasing use of artificial intelligence-based solutions.
No longer listed (1 heading from the year before)
Obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain. If we or our collaborators do not maintain regulatory approval for our marketed products, and obtain regulatory approval for our product candidates or new indications for our marketed products, we will not be able to market or sell them, which would materially and negatively impact our business, prospects, operating results, and financial condition.
Legal proceedings (Item 3)
The information called for by this item is incorporated herein by reference to the information set forth in Note 16 to our Consolidated Financial Statements included in this report.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 4, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
29 certified in FY2026 Q3, vs 61 a year earlier. 29 positions in total, median offered wage $155K a year.
Director Data Management · 2Manager Central Monitoring Data Analysis · 2Process Development Engineer III · 2Senior Scientist · 2Sr Associate Scientist · 2
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
FDA, last 12 months
4 approvals or clearances and 1 recall recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Legal
A securities lawsuit naming the company as a defendant was filed on Sep 23, 2026 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
A securities lawsuit naming the company as a defendant was filed on Jul 16, 2026 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). 1 case in that period is closed and not listed. Coverage of court records is not complete, and shareholder derivative suits are not included.
Short sale volume: 46.0% of the volume reported to FINRA over the last 20 trading days was marked short, close to its 1-year average of 46.9%. FINRA daily files, to Nov 18, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Off-exchange trading: 42.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (28.9% on ATS, 13.1% with other brokers), close to its 26-week average of 42.9%. Weeks of Oct 5 to Oct 30, 2026.
Week of May 4ATSOther off-exchangeFull height = all shares tradedWeek of Oct 26
Largest ATS: SIGMA X2 (14.1%), UBS ATS (12.7%), INTELLIGENT CROSS LLC (11.8%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
People read Regeneron Pharmaceuticals's Wikipedia article about 150 times a day over the last week, close to the 170 on a usual day of the three months before.
May 14, 2026Busiest day: 430 views on May 18, 2026Nov 18, 2026
Views of the article Regeneron Pharmaceuticals, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
When insiders usually buy
Last results
Oct 30, 2026
Within the 30 days after it, until Nov 29, 2026
Next results, expected
Jan 28, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
100%
28 of 28 insider purchases since 2017 came within 30 days after a results announcement
From Regeneron Pharmaceuticals's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Regeneron Pharmaceuticals's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Regeneron Pharmaceuticals filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 167 open-market sales (about $65.2M, in 25 filings, by 11 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 7 open-market sales (about $4.53M, in 2 filings). (Regeneron Pharmaceuticals on OQRO)
Congress. Members of Congress filed 4 disclosures on Regeneron Pharmaceuticals in the 12 months to Nov 19, 2026: 3 purchases and 1 sale, by 3 members. In the 12 months before that: 14 disclosures. The largest range: Rep. Gilbert Ray Cisneros Jr. (CA31), $1,001 to $15,000, filed Jun 8, 2026.
Funds and stakes. Fund 13F filings recorded in the 12 months show 52 new or larger positions and 51 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. 17 lobbying reports naming the company were posted in the 12 months, reporting about $2.71M. The Federal Register published a notice, "Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal", on Oct 1, 2026, naming the company.
Company reports, price and press. Regeneron Pharmaceuticals filed a Form 8-K on Oct 30, 2026 (Item 2.02) that OQRO classes as: reported its results. Regeneron Pharmaceuticals filed a Form 8-K on Oct 6, 2026 (Items 1.01, 2.02, 8.01) that OQRO classes as: signed an important agreement, and reported its results (and 1 more item).
Who holds it. 1,330 funds reported a stake in Regeneron Pharmaceuticals in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (9.9% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (7.2% of the value reported), Dodge & Cox (5.3% of the value reported).
Attention. The English Wikipedia article on Regeneron Pharmaceuticals was read about 147 times a day in the 7 days to Nov 18, 2026, against a usual 171 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. A filed suit is a claim, not a finding; many securities suits are dismissed or settled without any finding of fault.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Regeneron Pharmaceuticals filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 167 open-market sales (about $65.2M, in 25 filings, by 11 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 7 open-market sales (about $4.53M, in 2 filings).
The largest sale: George L Sing, Director, about $6.83M, filed Nov 4, 2026.
Congress
Members of Congress filed 4 disclosures on Regeneron Pharmaceuticals in the 12 months to Nov 19, 2026: 3 purchases and 1 sale, by 3 members. In the 12 months before that: 14 disclosures.
The largest range: Rep. Gilbert Ray Cisneros Jr. (CA31), $1,001 to $15,000, filed Jun 8, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 52 new or larger positions and 51 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
17 lobbying reports naming the company were posted in the 12 months, reporting about $2.71M.
The Federal Register published a notice, "Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal", on Oct 1, 2026, naming the company.
The Federal Register published a notice, "Issuance of Priority Review Voucher; Rare Pediatric Disease Product; OTARMENI (lunsotogene parvec-cwha)", on May 6, 2026, naming the company.
FDA records list 5 drug approvals, 1 recall for Regeneron Pharmaceuticals between Nov 19, 2025 and Nov 19, 2026; the latest, on Aug 19, 2026: drug approval for Pasatru (Biologic approved. Active ingredient: Garetosmab-Grts).
ClinicalTrials.gov shows 10 studys sponsored by the company updated in the period; the latest, "A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works..." (Phase 3, status active not recruiting), was updated on Nov 13, 2026, with primary completion listed for 2029-07-29.
Federal court records list 3 securities suits naming the company filed since Nov 19, 2024; the latest, "Hopkinson v. Regeneron Pharmaceuticals, Inc.", was filed Sep 23, 2026 in the District Court, S.D. New York and is still open.
FINRA short interest for REGN on the settlement date of Oct 30, 2026 was 2,217,114 shares (+3.85% on the previous report), about 2.73 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 54,601 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $7.28M for its principal executive officer, and an average of $7.73M for the other named executive officers.
Company reports, price and press
Regeneron Pharmaceuticals filed a Form 8-K on Oct 30, 2026 (Item 2.02) that OQRO classes as: reported its results.
Regeneron Pharmaceuticals filed a Form 8-K on Oct 6, 2026 (Items 1.01, 2.02, 8.01) that OQRO classes as: signed an important agreement, and reported its results (and 1 more item).
Regeneron Pharmaceuticals filed a Form 8-K on Sep 30, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "Effective September 24, 2026 (the ' Grant Date '), the Compensation Committee (the ' Compensation Committee ') of the Board of Directors (the ' Board ') of Regeneron Pharmaceuticals, Inc. (' Regeneron ' or the ' Company ') grante..."
Press coverage listed by Finnhub: "With FDA nod, Regeneron brings an RNAi drug to autoimmune disease" (Yahoo, Nov 19, 2026).
Press coverage listed by Finnhub: "REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis" (Yahoo, Nov 19, 2026).
Press coverage listed by Finnhub: "Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot" (Yahoo, Nov 19, 2026).
REGN closed at $945.53 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $782.04 to $945.53, a change of +20.9%.
Who holds it
1,330 funds reported a stake in Regeneron Pharmaceuticals in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (9.9% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (7.2% of the value reported), Dodge & Cox (5.3% of the value reported).
Attention
The English Wikipedia article on Regeneron Pharmaceuticals was read about 147 times a day in the 7 days to Nov 18, 2026, against a usual 171 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
A filed suit is a claim, not a finding; many securities suits are dismissed or settled without any finding of fault.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
38 active phase 3 trials and 54 active phase 2 trials led by this company, mostly in melanoma, atrial fibrillation (af), venous thromboembolism (vte). The ones with the nearest registered primary completion date still ahead:
9 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.